Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation. (LHGALOP2017)
Pediatric Hodgkin's Disease

About this trial
This is an interventional treatment trial for Pediatric Hodgkin's Disease focused on measuring Pediatric Hodgkin Lymphoma, therapy, reduced radiotherapy
Eligibility Criteria
Inclusion Criteria:
- Histopathological diagnosis of classical Hodgkin lymphoma.
- Normal renal, hepatic, pulmonary and metabolic function standards.
- Informed consent signed by patient and/or legal caretakers.
Exclusion Criteria:
- Lymphocyte predominant nodular Hodgkin lymphoma
- Any form of immunodeficiency before diagnosis. (primary immunodeficiencies, trasplant recipients or immunosuppressive therapies of any kind including corticoid therapies during 28 days before diagnosis).
- Pregnancy and breastfeeding period.
- Sexually active female patients who do not accept an effective contraceptive method during therapy.
- Positive HIV serology.
- Penfigus or hepatic ductopenia.
- Hodgkin lymphoma as a secondary malignant disease.
Sites / Locations
- Hospital JP GarrahanRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Group A
Group B
Group B2
Group C
Group D
Group E
Group F
Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered. No radiotherapy if CR at the end of chemotherapy.
Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered. No radiotherapy if CR at the end of chemotherapy
Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered. No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy
Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered. No radiotherapy if CR at the end of chemotherapy.
Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD. No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy
High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD. No radiotherapy if CR at the end of chemotherapy
High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD. No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy